Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants
Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.HAYWARD, Calif.--(BUSINESS WIRE)--Dec. 19, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, today announced that, on December 18, 2024, the Company's Co-Chairman and majority shareholder, Robert W. Duggan, exercised all of the warrants he acquired in the Company's 2024 rights offering, corresponding to $58.4 million totaling to 5,306,156 shares of Company common stock. Mr. Duggan also confirmed that, from December 11, 2024 through this past Friday, December 13, 2024, he has purchased an additional 156,714 shares of Pulse Biosciences. These transactions bring Mr. Duggan's current ownership in the Company to approximately 70%.
海沃德，加州.--（商業通訊）--2024年12月19日--Pulse Biosciences, Inc.（納斯達克：PLSE）（「公司」或「Pulse Biosciences」）是一家新型生物電醫學公司，商業化由納米脈衝刺激（NPS）技術驅動的CellFX系統，今天宣佈在2024年12月18日，公司聯合主席和主要股東羅伯特·W·杜幹行使了他在公司2024年配售中獲得的所有Warrants，相當於5840萬美元，共計5,306,156股公司普通股。杜幹先生還確認，從2024年12月11日到上週五，即2024年12月13日，他額外購買了156,714股Pulse Biosciences的股票。這些交易使杜幹先生在公司的當前持股量大約達到70%.
About Pulse Biosciences
關於Pulse Biosciences
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company's proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in Miami, Florida and maintains its office in Hayward, California.
Pulse Biosciences是一家致力於健康創新的生物電醫學公司，致力於改善患者的生活質量。公司的專有CellFX nsPFA技術通過非熱方式向細胞提供納秒脈衝電能，同時保護相鄰的非細胞組織。該公司正在積極推進CellFX nsPFA技術的開發，以用於治療房顫及其他幾個潛在對患者和提供者的醫療健康產生重大積極影響的市場。Pulse Biosciences目前總部位於佛羅里達州邁阿密，並在加利福尼亞州海沃德設有辦公室。
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
Pulse Biosciences、CellFX、納米脈衝刺激、NPS、nsPFA、CellFX nsPFA及其風格化標誌是Pulse Biosciences, Inc.在美國及其他國家的商標和/或註冊商標。
View source version on businesswire.com:
在businesswire.com查看源版本：
Investors:
Pulse Biosciences, Inc.
Darrin Uecker, CTO or Kevin Danahy, CCO
IR@pulsebiosciences.com
or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
投資者：
脈衝生物科學公司
達林·尤克，首席技術官或凱文·丹納赫，首席商務官
IR@pulsebiosciences.com
或
吉爾馬丁集團
菲利普·特里普·泰勒
415.937.5406
philip@gilmartinir.com
Rights Offering Information, Subscription and Warrant Agent:
Broadridge Corporate Issuer Solutions, LLC
Attn: BCIS Re-Organization Dept.
P.O. Box 1317
Brentwood, NY 11717-0718
888.789.8409
shareholder@broadridge.com
權利發行信息，認購及Warrants代理：
Broadridge企業發行解決方案公司
注意：BCIS重組部門。
郵政信箱1317
紐約布倫特伍德，郵政編碼11717-0718
888.789.8409
shareholder@broadridge.com
Source: Pulse Biosciences, Inc.
來源：Pulse Biosciences, Inc.
